PubMed · 7697111
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
U Nirenberg. 1994. Reversed-phase HPLC. Analytical procedure.. https://doi.org/10.1385/0-89603-274-4%3A23
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The effect of the number of functional units on a monomer on the elution property of dental composites was first studied. Elution from a composite of a trifunctional methacrylate, 1,1,1-tris[4-(2'-hydroxy-3'-methacryloyloxypropoxy)phenyl]ethane (THMPE), was compared to that of bis-GMA, a typical difunctional base monomer in current dental composites. The degrees of cure and the water solubilities of composites prepared from the two kinds of methacrylates were measured. The concentration of unreacted methacrylates (base monomer and diluent) present in the photo-cured composites as well as the quantity of the methacrylates eluted into water (or 75%, volume fraction, of ethanol in water) from the composites were determined by high-performance liquid chromatography (HPLC). THMPE-based composites showed lesser amounts of residual and eluted methacrylates when compared with bis-GMA composites. This is attributed to the higher degree of functionality and larger molecular size of THMPE compared with those of bis-GMA.
A practicable and selective liquid chromatography-mass spectrometry assay for the determination of two cyclooxygenase-2 inhibitors, etoricoxib and valdecoxib, in human plasma is presented. The analytical technique is based on reversed-phase high-performance liquid chromatography (HPLC) coupled to atmospheric pressure chemical ionisation (APCI) mass spectrometry (Finnigan Mat LCQ ion trap). Mass analysis was performed in the positive ion mode. The ion trap was operated in the tandem MS mode (MS2) and the transitions of etoricoxib (m/z 359.2 --> 280.3) and valdecoxib (m/z 315.1 --> 235.1) were followed by selected reaction monitoring. Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively. The method was validated over a linear range 10-2500 and 5-1000 microg/L using the other substrate as internal standard. After validation, the method was used to study the pharmacokinetic pro fi le of etoricoxib or valdecoxib in a healthy volunteer after administration of a single oral dose (valdecoxib, 20 mg; etoricoxib, 90 mg). The presented method was suf fi cient to cover more than 90% of the area under the plasma concentration time curve.
A validated high performance liquid chromatographic method was developed for the determination of chromium picolinate in pharmaceutical dosage forms. The analysis was performed at room temperature using a reversed-phase Supelcosil LC-18 (250 x 4.6 mm, 5 microm) column. The mobile phase consisted of acetonitrile:water (40:60 v/v) at a fl ow rate of 0.8 mL/min. The UV-detector was set at 264 nm. The developed method showed a good linear relationship in the concentration range from 0.125 to 12.5 microg/mL with a correlation coefficient from 0.999. The limit of detection and limit of quanti fi cation were 0.091 and 0.181 microg/mL, respectively.